Genmab — Maj 2018
-
Newly-diagnosed Multiple Myeloma
Abstract #PS1429; Poster Presentation; Saturday, June 16, 17:30 - 19:00. Cost comparison of treatment strategies following initiation with Rd versus VMP plus daratumumab in newly diagnosed patients ineligible for ASCT. (Jackson)
-
1220 virker som en stærk støtte. Derudover ser det ud som om vi skal svinge mellem 1200-1300 indtil der kommer afgørende nyt.
-
Spørgsmålet er så om nuværende kurs er fair value.
-
Paul Parren, the former head of preclinical R&D at Genmab, has joined Lava as head of R&D https://endpts.com/versant-backs-new-approach-to-gamma-delta-t-cells-co-leads-lavas-18-9m-round/ https://www.fiercebiotech.com/biotech/lava-bags-cash-from-gilde-and-versant-hires-genmab-vet-to-advance-bispecific-t-cell
-
Ikke hvem som helst: He is an inventor of the therapeutic antibodies ofatumumab (approved world-wide), daratumumab (phase III), teprotumumab (Phase II), TF-011-ADC (Phase I) and the DuoBody and HexaBody technologies. https://www.antibodysociety.org/about/board-of-directors/paul-parren-ph-d/
-
ASCO 2018: Helpful Guidance, But No Breakthroughs https://www.myeloma.org/blog/dr-duries/asco-2018-helpful-guidance-no-breakthroughs
-
Ola Landgren vil ikke afvise brug af Alcyone-kombien i US https://www.youtube.com/watch?v=Yp8wdwlcDrs
-
Genialt indslag med Florian på Børsen Play : https://play.borsen.dk/klip/5b04f95b45628ff817223c22/medstifter_og_storinvestor_i_genmab_risikobilledet_i_investorernes_oejne_har_aendret_sig.html
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind